Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242701 | 0.90 | RAF1 (1.00) | RAF1MAPK14MEN1KMT2AMAPT | |
| SCHEMBL3245493 | 0.88 | RAF1 (0.83) | RAF1MAPK14MAPTNPC1RAB9A | |
| SCHEMBL12856580 | 0.88 | MAPK14 (1.00) | RAF1MAPK14MEN1KMT2AMAPT | |
| SCHEMBL3226646 | 0.82 | MAPK14 (1.00) | RAF1MAPK14MAPTALDH1A1 | |
| SCHEMBL3241448 | 0.80 | MAPK14 (1.00) | RAF1MAPK14MEN1KMT2AMAPT | |
| SCHEMBL3234900 | 0.80 | MAPK14 (0.77) | RAF1MAPK14MAPTHTTNPC1 | |
| SCHEMBL3237561 | 0.79 | MAPK14 (1.00) | RAF1MAPK14MEN1KMT2A | |
| SCHEMBL3241506 | 0.72 | MAPK14 (1.00) | RAF1MAPK14MEN1KMT2AMAPT | |
| SCHEMBL4246258 | 0.71 | RAB9A (0.60) | RAF1MEN1KMT2AMAPTCASP3 | |
| SCHEMBL14600409 | 0.70 | MEN1 (0.66) | MEN1KMT2AMAPTCASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | claimed |
| JP-4344960-B2 | — | — | 2009-10-14 | — | — | JP | claimed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | claimed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | claimed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | claimed |
| JP-2001526687-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | claimed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | RAF1 237/4885MAPK14 40/4885MEN1 4239/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | RAF1 237/4885MAPK14 40/4885MEN1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.